United States - English - NLM (National Library of Medicine)

a-s medication solutions - etanercept (unii: op401g7ojc) (etanercept - unii:op401g7ojc) - enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (ra). enbrel can be initiated in combination with methotrexate (mtx) or used alone. enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients ages 2 and older. enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (psa). enbrel can be used with or without methotrexate. enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (as). enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (pso) who are candidates for systemic therapy or phototherapy. enbrel

United States - English - NLM (National Library of Medicine)

a-s medication solutions - etanercept (unii: op401g7ojc) (etanercept - unii:op401g7ojc) - enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (ra). enbrel can be initiated in combination with methotrexate (mtx) or used alone. enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients ages 2 and older. enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (psa). enbrel can be used with or without methotrexate. enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (as). enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (pso) who are candidates for systemic therapy or phototherapy. enbrel

United States - English - NLM (National Library of Medicine)

a-s medication solutions - etanercept (unii: op401g7ojc) (etanercept - unii:op401g7ojc) - enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (ra). enbrel can be initiated in combination with methotrexate (mtx) or used alone. enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (jia) in patients ages 2 and older. enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (psa). enbrel can be used with or without methotrexate. enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (as). enbrel is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (pso) who are candidates for systemic therapy or phototherapy. enbrel

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - etanercept 25mg - powder for injection with diluent - 25 mg - active: etanercept 25mg excipient: mannitol nitrogen sucrose trometamol water for injection - the treatment of active, rheumatoid arthritis in adults where classical anitrheumatic therapy is insufficient or inappropriate. enbrel treatment decreases disease activity, increases functional ability, and improves health-related quality of life. enbrel is also effective in combination with methotrexate. the treatment of active, adult rheumatoid arthritis to slow progression of disease-associated structural damage as measured by x-ray.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - etanercept 50mg;   - powder for injection with diluent - 50 mg - active: etanercept 50mg   excipient: mannitol nitrogen sucrose trometamol water for injection - the treatment of active, rheumatoid arthritis in adults where classical anitrheumatic therapy is insufficient or inappropriate. enbrel treatment decreases disease activity, increases functional ability, and improves health-related quality of life. enbrel is also effective in combination with methotrexate. the treatment of active, adult rheumatoid arthritis to slow progression of disease-associated structural damage as measured by x-ray.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - etanercept 25mg - solution for injection - 25 mg - active: etanercept 25mg excipient: arginine hydrochloride dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride sucrose water for injection - the treatment of active, rheumatoid arthritis in adults where classical anitrheumatic therapy is insufficient or inappropriate. enbrel treatment decreases disease activity, increases functional ability, and improves health-related quality of life. enbrel is also effective in combination with methotrexate. the treatment of active, adult rheumatoid arthritis to slow progression of disease-associated structural damage as measured by x-ray.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - etanercept 50mg - solution for injection - 50 mg - active: etanercept 50mg excipient: arginine hydrochloride dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride sucrose water for injection - the treatment of active, rheumatoid arthritis in adults where classical anitrheumatic therapy is insufficient or inappropriate. enbrel treatment decreases disease activity, increases functional ability, and improves health-related quality of life. enbrel is also effective in combination with methotrexate. the treatment of active, adult rheumatoid arthritis to slow progression of disease-associated structural damage as measured by x-ray.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - water for injections; etanercept -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - etanercept, quantity: 25 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; sucrose; sodium chloride; water for injections; arginine hydrochloride - enbrel is indicated for the treatment of: adults rheumatoid arthritis active, adult rheumatoid arthritis (ra) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (dmards). enbrel can be used in combination with methotrexate. severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease. psoriatic arthritis the signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. enbrel has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function. plaque psoriasis adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy. ankylosing spondylitis the signs and symptoms of active ankylosing spondylitis in adults. non-radiographic axial spondyloarthritis treatment of adults with active* non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or mri change who have had an inadequate response to nsaids . * active disease is defined as a bath ankylosing spondylitis disease activity index (basdai) score of greater than or equal to 4.,children and adolescents juvenile idiopathic arthritis active polyarthritis (rheumatoid factor positive or negative) in children and adolescents, aged 2 to 17 years, who have had an inadequate response to one or more dmards. active extended oligoarthritis in children and adolescents, aged 2 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. active enthesitis-related arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, conventional therapy. active psoriatic arthritis in adolescents, aged 12 to 17 years, who have had an inadequate response to, or who have proved intolerant to, methotrexate. enbrel has not been studied in children aged less than 2 years. paediatric plaque psoriasis chronic, severe plaque psoriasis in children and adolescents from 4 to 17 years, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. duration of therapy to be no longer than 24 weeks and treatment to be ceased after 12 weeks if a significant pasi response is not achieved.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - etanercept - powder and solvent for solution for injection - 25mg